Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.78
NKTR's Cash to Debt is ranked higher than
58% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. NKTR: 1.78 )
NKTR' s 10-Year Cash to Debt Range
Min: 0.73   Max: 46.5
Current: 1.78

0.73
46.5
Equity to Asset 0.08
NKTR's Equity to Asset is ranked higher than
51% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NKTR: 0.08 )
NKTR' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.87
Current: 0.08

-0.21
0.87
F-Score: 5
Z-Score: -2.58
M-Score: -1.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -8.21
NKTR's Operating margin (%) is ranked higher than
81% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. NKTR: -8.21 )
NKTR' s 10-Year Operating margin (%) Range
Min: -331.7   Max: -8.21
Current: -8.21

-331.7
-8.21
Net-margin (%) -26.86
NKTR's Net-margin (%) is ranked higher than
77% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. NKTR: -26.86 )
NKTR' s 10-Year Net-margin (%) Range
Min: -322.72   Max: -12
Current: -26.86

-322.72
-12
ROA (%) -11.63
NKTR's ROA (%) is ranked higher than
78% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. NKTR: -11.63 )
NKTR' s 10-Year ROA (%) Range
Min: -38.56   Max: -4.39
Current: -11.63

-38.56
-4.39
ROC (Joel Greenblatt) (%) -23.05
NKTR's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. NKTR: -23.05 )
NKTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -203.29   Max: -24.01
Current: -23.05

-203.29
-24.01
Revenue Growth (3Y)(%) 35.90
NKTR's Revenue Growth (3Y)(%) is ranked higher than
94% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. NKTR: 35.90 )
NKTR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -31.4   Max: 59.6
Current: 35.9

-31.4
59.6
EBITDA Growth (3Y)(%) -72.40
NKTR's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NKTR: -72.40 )
NKTR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -72.4   Max: 108
Current: -72.4

-72.4
108
EPS Growth (3Y)(%) -29.30
NKTR's EPS Growth (3Y)(%) is ranked higher than
62% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NKTR: -29.30 )
NKTR' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.4   Max: 101
Current: -29.3

-44.4
101
» NKTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NKTR Guru Trades in Q1 2014

PRIMECAP Management 15,534,086 sh (+24.29%)
Steven Cohen Sold Out
» More
Q2 2014

NKTR Guru Trades in Q2 2014

PRIMECAP Management 15,804,286 sh (+1.74%)
» More
Q3 2014

NKTR Guru Trades in Q3 2014

PRIMECAP Management 18,137,786 sh (+14.76%)
» More
Q4 2014

NKTR Guru Trades in Q4 2014

Stanley Druckenmiller 655,000 sh (New)
Jim Simons 432,148 sh (New)
Paul Tudor Jones 11,698 sh (New)
PRIMECAP Management 18,225,786 sh (+0.49%)
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 21.69
NKTR's Forward P/E is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NKTR: 21.69 )
N/A
P/B 38.40
NKTR's P/B is ranked lower than
62% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. NKTR: 38.40 )
NKTR' s 10-Year P/B Range
Min: 1.72   Max: 58
Current: 38.4

1.72
58
P/S 7.00
NKTR's P/S is ranked higher than
83% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. NKTR: 7.00 )
NKTR' s 10-Year P/S Range
Min: 1.76   Max: 16.68
Current: 7

1.76
16.68
Current Ratio 4.50
NKTR's Current Ratio is ranked higher than
73% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. NKTR: 4.50 )
NKTR' s 10-Year Current Ratio Range
Min: 1   Max: 16.32
Current: 4.5

1
16.32
Quick Ratio 4.30
NKTR's Quick Ratio is ranked higher than
73% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. NKTR: 4.30 )
NKTR' s 10-Year Quick Ratio Range
Min: 0.96   Max: 16.32
Current: 4.3

0.96
16.32
Days Inventory 166.51
NKTR's Days Inventory is ranked higher than
83% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NKTR: 166.51 )
NKTR' s 10-Year Days Inventory Range
Min: 33.21   Max: 247.21
Current: 166.51

33.21
247.21
Days Sales Outstanding 6.56
NKTR's Days Sales Outstanding is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. NKTR: 6.56 )
NKTR' s 10-Year Days Sales Outstanding Range
Min: 5.46   Max: 79.04
Current: 6.56

5.46
79.04

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.80
NKTR's Price/Median PS Value is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. NKTR: 0.80 )
NKTR' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 4.42
Current: 0.8

0.24
4.42
Earnings Yield (Greenblatt) -1.20
NKTR's Earnings Yield (Greenblatt) is ranked higher than
82% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NKTR: -1.20 )
NKTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.3   Max: 0
Current: -1.2

-1.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ITH.Germany,
Nektar Therapeutics, Inc., was incorporated in July 1990 and reincorporated in Delaware in 1998. The Company is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities. The Company's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company also has a collaboration with Bayer Healthcare LLC "Bayer" to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. Bayer has initiated a Phase 3 clinical development of BAY41-6551 with the first patient enrolled in April 2013. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.
» More Articles for NKTR

Headlines

Articles On GuruFocus.com
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on NKTR May 01 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 


More From Other Websites
Baxter (BAX) Beats Q1 Earnings Estimates, Sales Down Y/Y - Analyst Blog Apr 24 2015
Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After... Apr 23 2015
Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After... Apr 23 2015
Will Baxter's (BAX) Earnings Disappoint Estimates in Q1? - Analyst Blog Apr 21 2015
Baxter (BAX) Presents Positive Phase 3 Data for BAX 111 - Analyst Blog Apr 20 2015
5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015 Apr 18 2015
Baxter Files New Drug Application for BAX 855 in Japan - Analyst Blog Apr 17 2015
Huge Biotech Index Rebalance Means Massive Buy Orders for These 4 Stocks Apr 17 2015
Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant... Apr 16 2015
Baxter Submits Application to Japan’s MHLW for Approval of BAX 855, Extended Half-Life Recombinant... Apr 16 2015
Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
Nektar Gets Movantik Milestone Payment from AstraZeneca - Analyst Blog Apr 06 2015
Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca Apr 02 2015
Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca Apr 02 2015
MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients... Mar 31 2015
MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients... Mar 31 2015
AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog Mar 20 2015
AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US Mar 19 2015
Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics Mar 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK